Increased vimentin in human α- and β-cells in type 2 diabetes

Maaike Roefs, Françoise Carlotti, Katherine Jones, Hannah Wills, Alexander Hamilton, Michael Verschoor, Joanna Williams Durkin, Laura Garcia-Perez, Melissa Brereton, Laura McCulloch, Marten Engelse, Paul Johnson, Barbara Hansen, Kevin Docherty, Eelco de Koning, Anne Clark (Corresponding Author)

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Type 2 diabetes (T2DM) is associated with pancreatic islet dysfunction. Loss of β-cell identity has been implicated via dedifferentiation or conversion to other pancreatic endocrine cell types. How these transitions contribute to the onset and progression of T2DM in vivo is unknown. The aims of this study were to determine the degree of epithelial-to-mesenchymal transition occurring in α and β cells in vivo and to relate this to diabetes-associated (patho)physiological conditions. The proportion of islet cells expressing the mesenchymal marker vimentin was determined by immunohistochemistry and quantitative morphometry in specimens of pancreas from human donors with (T2DM, n=28) and without diabetes (ND, n=38), and in non-human primates at different stages of the diabetic syndrome; normoglycaemic (ND, n=4), obese, hyperinsulinaemic (HI, n=4) and hyperglycaemic (DM, n=8). Vimentin co-localised more frequently with glucagon (α-cells) than with insulin (β-cells) in the human ND group (1.43% total α-cells, 0.98% total β-cells, median; p<0.05); these proportions were higher in T2DM than ND (median 4.53% α- , 2.53% β-cells; p<0.05). Vimentin-positive β-cells were not apoptotic, had reduced expression of Nkx6.1 and Pdx-1 and were not associated with islet amyloidosis or with bihormonal expression (insulin+glucagon). In non-human primates, vimentin-positive β-cell proportion was larger in the diabetic than the ND group (12.08% vs. 0.45%, respectively, p<0.05), whereas it was similar in ND and HI groups. In conclusion, islet cell expression of vimentin indicates a degree of plasticity and dedifferentiation with potential loss of cellular identity in diabetes. This could contribute to α- and β-cell dysfunction in T2DM.

Original languageEnglish
Pages (from-to)217-227
Number of pages11
JournalJournal of Endocrinology
Volume233
Issue number3
Early online date27 Mar 2017
DOIs
Publication statusPublished - 1 Jun 2017

Fingerprint

Vimentin
Type 2 Diabetes Mellitus
Islets of Langerhans
Glucagon
Primates
Insulin
Epithelial-Mesenchymal Transition
Endocrine Cells
Amyloidosis
Pancreas
Immunohistochemistry

Keywords

  • Amyloid
  • differentiation
  • EMT
  • non-human primate
  • islet
  • glucagon
  • insulin

Cite this

Roefs, M., Carlotti, F., Jones, K., Wills, H., Hamilton, A., Verschoor, M., ... Clark, A. (2017). Increased vimentin in human α- and β-cells in type 2 diabetes. Journal of Endocrinology, 233(3), 217-227. https://doi.org/10.1530/JOE-16-0588

Increased vimentin in human α- and β-cells in type 2 diabetes. / Roefs, Maaike; Carlotti, Françoise; Jones, Katherine; Wills, Hannah; Hamilton, Alexander; Verschoor, Michael; Williams Durkin, Joanna; Garcia-Perez, Laura; Brereton, Melissa; McCulloch, Laura; Engelse, Marten; Johnson, Paul; Hansen, Barbara; Docherty, Kevin; de Koning, Eelco; Clark, Anne (Corresponding Author).

In: Journal of Endocrinology, Vol. 233, No. 3, 01.06.2017, p. 217-227.

Research output: Contribution to journalArticle

Roefs, M, Carlotti, F, Jones, K, Wills, H, Hamilton, A, Verschoor, M, Williams Durkin, J, Garcia-Perez, L, Brereton, M, McCulloch, L, Engelse, M, Johnson, P, Hansen, B, Docherty, K, de Koning, E & Clark, A 2017, 'Increased vimentin in human α- and β-cells in type 2 diabetes', Journal of Endocrinology, vol. 233, no. 3, pp. 217-227. https://doi.org/10.1530/JOE-16-0588
Roefs M, Carlotti F, Jones K, Wills H, Hamilton A, Verschoor M et al. Increased vimentin in human α- and β-cells in type 2 diabetes. Journal of Endocrinology. 2017 Jun 1;233(3):217-227. https://doi.org/10.1530/JOE-16-0588
Roefs, Maaike ; Carlotti, Françoise ; Jones, Katherine ; Wills, Hannah ; Hamilton, Alexander ; Verschoor, Michael ; Williams Durkin, Joanna ; Garcia-Perez, Laura ; Brereton, Melissa ; McCulloch, Laura ; Engelse, Marten ; Johnson, Paul ; Hansen, Barbara ; Docherty, Kevin ; de Koning, Eelco ; Clark, Anne. / Increased vimentin in human α- and β-cells in type 2 diabetes. In: Journal of Endocrinology. 2017 ; Vol. 233, No. 3. pp. 217-227.
@article{2d110bc8a6a9449591f2466aa374a682,
title = "Increased vimentin in human α- and β-cells in type 2 diabetes",
abstract = "Type 2 diabetes (T2DM) is associated with pancreatic islet dysfunction. Loss of β-cell identity has been implicated via dedifferentiation or conversion to other pancreatic endocrine cell types. How these transitions contribute to the onset and progression of T2DM in vivo is unknown. The aims of this study were to determine the degree of epithelial-to-mesenchymal transition occurring in α and β cells in vivo and to relate this to diabetes-associated (patho)physiological conditions. The proportion of islet cells expressing the mesenchymal marker vimentin was determined by immunohistochemistry and quantitative morphometry in specimens of pancreas from human donors with (T2DM, n=28) and without diabetes (ND, n=38), and in non-human primates at different stages of the diabetic syndrome; normoglycaemic (ND, n=4), obese, hyperinsulinaemic (HI, n=4) and hyperglycaemic (DM, n=8). Vimentin co-localised more frequently with glucagon (α-cells) than with insulin (β-cells) in the human ND group (1.43{\%} total α-cells, 0.98{\%} total β-cells, median; p<0.05); these proportions were higher in T2DM than ND (median 4.53{\%} α- , 2.53{\%} β-cells; p<0.05). Vimentin-positive β-cells were not apoptotic, had reduced expression of Nkx6.1 and Pdx-1 and were not associated with islet amyloidosis or with bihormonal expression (insulin+glucagon). In non-human primates, vimentin-positive β-cell proportion was larger in the diabetic than the ND group (12.08{\%} vs. 0.45{\%}, respectively, p<0.05), whereas it was similar in ND and HI groups. In conclusion, islet cell expression of vimentin indicates a degree of plasticity and dedifferentiation with potential loss of cellular identity in diabetes. This could contribute to α- and β-cell dysfunction in T2DM.",
keywords = "Amyloid, differentiation, EMT, non-human primate, islet, glucagon, insulin",
author = "Maaike Roefs and Fran{\cc}oise Carlotti and Katherine Jones and Hannah Wills and Alexander Hamilton and Michael Verschoor and {Williams Durkin}, Joanna and Laura Garcia-Perez and Melissa Brereton and Laura McCulloch and Marten Engelse and Paul Johnson and Barbara Hansen and Kevin Docherty and {de Koning}, Eelco and Anne Clark",
year = "2017",
month = "6",
day = "1",
doi = "10.1530/JOE-16-0588",
language = "English",
volume = "233",
pages = "217--227",
journal = "Journal of Endocrinology",
issn = "0022-0795",
publisher = "Society for Endocrinology",
number = "3",

}

TY - JOUR

T1 - Increased vimentin in human α- and β-cells in type 2 diabetes

AU - Roefs, Maaike

AU - Carlotti, Françoise

AU - Jones, Katherine

AU - Wills, Hannah

AU - Hamilton, Alexander

AU - Verschoor, Michael

AU - Williams Durkin, Joanna

AU - Garcia-Perez, Laura

AU - Brereton, Melissa

AU - McCulloch, Laura

AU - Engelse, Marten

AU - Johnson, Paul

AU - Hansen, Barbara

AU - Docherty, Kevin

AU - de Koning, Eelco

AU - Clark, Anne

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Type 2 diabetes (T2DM) is associated with pancreatic islet dysfunction. Loss of β-cell identity has been implicated via dedifferentiation or conversion to other pancreatic endocrine cell types. How these transitions contribute to the onset and progression of T2DM in vivo is unknown. The aims of this study were to determine the degree of epithelial-to-mesenchymal transition occurring in α and β cells in vivo and to relate this to diabetes-associated (patho)physiological conditions. The proportion of islet cells expressing the mesenchymal marker vimentin was determined by immunohistochemistry and quantitative morphometry in specimens of pancreas from human donors with (T2DM, n=28) and without diabetes (ND, n=38), and in non-human primates at different stages of the diabetic syndrome; normoglycaemic (ND, n=4), obese, hyperinsulinaemic (HI, n=4) and hyperglycaemic (DM, n=8). Vimentin co-localised more frequently with glucagon (α-cells) than with insulin (β-cells) in the human ND group (1.43% total α-cells, 0.98% total β-cells, median; p<0.05); these proportions were higher in T2DM than ND (median 4.53% α- , 2.53% β-cells; p<0.05). Vimentin-positive β-cells were not apoptotic, had reduced expression of Nkx6.1 and Pdx-1 and were not associated with islet amyloidosis or with bihormonal expression (insulin+glucagon). In non-human primates, vimentin-positive β-cell proportion was larger in the diabetic than the ND group (12.08% vs. 0.45%, respectively, p<0.05), whereas it was similar in ND and HI groups. In conclusion, islet cell expression of vimentin indicates a degree of plasticity and dedifferentiation with potential loss of cellular identity in diabetes. This could contribute to α- and β-cell dysfunction in T2DM.

AB - Type 2 diabetes (T2DM) is associated with pancreatic islet dysfunction. Loss of β-cell identity has been implicated via dedifferentiation or conversion to other pancreatic endocrine cell types. How these transitions contribute to the onset and progression of T2DM in vivo is unknown. The aims of this study were to determine the degree of epithelial-to-mesenchymal transition occurring in α and β cells in vivo and to relate this to diabetes-associated (patho)physiological conditions. The proportion of islet cells expressing the mesenchymal marker vimentin was determined by immunohistochemistry and quantitative morphometry in specimens of pancreas from human donors with (T2DM, n=28) and without diabetes (ND, n=38), and in non-human primates at different stages of the diabetic syndrome; normoglycaemic (ND, n=4), obese, hyperinsulinaemic (HI, n=4) and hyperglycaemic (DM, n=8). Vimentin co-localised more frequently with glucagon (α-cells) than with insulin (β-cells) in the human ND group (1.43% total α-cells, 0.98% total β-cells, median; p<0.05); these proportions were higher in T2DM than ND (median 4.53% α- , 2.53% β-cells; p<0.05). Vimentin-positive β-cells were not apoptotic, had reduced expression of Nkx6.1 and Pdx-1 and were not associated with islet amyloidosis or with bihormonal expression (insulin+glucagon). In non-human primates, vimentin-positive β-cell proportion was larger in the diabetic than the ND group (12.08% vs. 0.45%, respectively, p<0.05), whereas it was similar in ND and HI groups. In conclusion, islet cell expression of vimentin indicates a degree of plasticity and dedifferentiation with potential loss of cellular identity in diabetes. This could contribute to α- and β-cell dysfunction in T2DM.

KW - Amyloid

KW - differentiation

KW - EMT

KW - non-human primate

KW - islet

KW - glucagon

KW - insulin

UR - http://www.scopus.com/inward/record.url?scp=85019993664&partnerID=8YFLogxK

U2 - 10.1530/JOE-16-0588

DO - 10.1530/JOE-16-0588

M3 - Article

VL - 233

SP - 217

EP - 227

JO - Journal of Endocrinology

JF - Journal of Endocrinology

SN - 0022-0795

IS - 3

ER -